Allogeneic hematopoietic cell transplant for relapsed-refractory, marginal zone lymphoma: a single-center experience

Leuk Lymphoma. 2018 Nov;59(11):2727-2730. doi: 10.1080/10428194.2018.1452220. Epub 2018 Mar 23.

Authors

Bhagirathbhai R Dholaria¹, William A Hammond², Vivek Roy³, Taimur Sher³, Prakash Vishnu³, Aixa Soyano³, Laura E Finn⁴, Han Tun³

Affiliations

¹ a Department of Blood and Marrow Transplant and Cellular Immunotherapy , Moffitt Cancer Center , Tampa , FL , USA.
² b Department of Malignant Hematology , Baptist M.D. Anderson Cancer Center , Jacksonville , FL , USA.
³ c Department of Hematology and Oncology , Mayo Clinic , Jacksonville , FL , USA.
⁴ d Division of Hematology and Oncology , Ochsner Medical Center , New Orleans , LA , USA.

PMID: 29566563
DOI: 10.1080/10428194.2018.1452220

No abstract available

Publication types

Letter

MeSH terms

Adult
Drug Resistance, Neoplasm
Female
Hematopoietic Stem Cell Transplantation / methods*
Humans
Kaplan-Meier Estimate
Lymphoma, B-Cell, Marginal Zone / pathology
Lymphoma, B-Cell, Marginal Zone / therapy*
Male
Middle Aged
Neoplasm Recurrence, Local
Retrospective Studies
Transplantation, Homologous